
USA - NASDAQ:UTRS - US60343F2056 - Common Stock
The current stock price of UTRS is 1.48 USD. In the past month the price decreased by -5.13%. In the past year, price decreased by -66.88%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 26.17 | 227.29B | ||
| ISRG | INTUITIVE SURGICAL INC | 63.82 | 196.99B | ||
| BSX | BOSTON SCIENTIFIC CORP | 34.81 | 152.16B | ||
| SYK | STRYKER CORP | 27.5 | 138.48B | ||
| IDXX | IDEXX LABORATORIES INC | 54.71 | 55.19B | ||
| BDX | BECTON DICKINSON AND CO | 13.39 | 55.33B | ||
| EW | EDWARDS LIFESCIENCES CORP | 33.58 | 50.67B | ||
| RMD | RESMED INC | 24.69 | 35.68B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 15.94 | 33.40B | ||
| DXCM | DEXCOM INC | 31.22 | 22.77B | ||
| PODD | INSULET CORP | 72.8 | 23.42B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.11 | 17.81B |
Minerva Surgical Inc is a US-based company operating in Health Care Equipment & Supplies industry. The company is headquartered in Redwood City, California and currently employs 174 full-time employees. The company went IPO on 2021-10-22. Minerva Surgical, Inc. is a commercial-stage medical technology company focused on developing, manufacturing, and commercializing minimally invasive solutions to meet the distinct uterine healthcare needs of women. The company has established a product line of commercially available, minimally invasive alternatives to hysterectomy, which are designed to address the most common causes of Abnormal Uterine Bleeding (AUB) in most uterine anatomies. Its Minerva Surgical solutions can be used in a variety of medical treatment settings and aim to address the drawbacks associated with alternative treatment methods and to preserve the uterus by avoiding unnecessary hysterectomies. The company offers a range of solutions, such as the Minerva ES Endometrial Ablation System (Minerva ES), Genesys HTA Endometrial Ablation System (Genesys HTA), Symphion Tissue Removal System (Symphion), and Resectr Tissue Resection Device (Resectr). Minerva ES is an endometrial ablation device that utilizes its PlasmaSense technology.
MINERVA SURGICAL INC
101 Saginaw Drive
Redwood City CALIFORNIA US
Employees: 174
Phone: 16502843500
Minerva Surgical Inc is a US-based company operating in Health Care Equipment & Supplies industry. The company is headquartered in Redwood City, California and currently employs 174 full-time employees. The company went IPO on 2021-10-22. Minerva Surgical, Inc. is a commercial-stage medical technology company focused on developing, manufacturing, and commercializing minimally invasive solutions to meet the distinct uterine healthcare needs of women. The company has established a product line of commercially available, minimally invasive alternatives to hysterectomy, which are designed to address the most common causes of Abnormal Uterine Bleeding (AUB) in most uterine anatomies. Its Minerva Surgical solutions can be used in a variety of medical treatment settings and aim to address the drawbacks associated with alternative treatment methods and to preserve the uterus by avoiding unnecessary hysterectomies. The company offers a range of solutions, such as the Minerva ES Endometrial Ablation System (Minerva ES), Genesys HTA Endometrial Ablation System (Genesys HTA), Symphion Tissue Removal System (Symphion), and Resectr Tissue Resection Device (Resectr). Minerva ES is an endometrial ablation device that utilizes its PlasmaSense technology.
The current stock price of UTRS is 1.48 USD. The price decreased by -4.52% in the last trading session.
UTRS does not pay a dividend.
UTRS has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
MINERVA SURGICAL INC (UTRS) will report earnings on 2024-03-19, after the market close.
You can find the ownership structure of MINERVA SURGICAL INC (UTRS) on the Ownership tab.
The outstanding short interest for MINERVA SURGICAL INC (UTRS) is 0% of its float.
ChartMill assigns a fundamental rating of 2 / 10 to UTRS. Both the profitability and financial health of UTRS have multiple concerns.
Over the last trailing twelve months UTRS reported a non-GAAP Earnings per Share(EPS) of -8.21. The EPS increased by 58.66% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -45.95% | ||
| ROE | -164.78% | ||
| Debt/Equity | 1.37 |
7 analysts have analysed UTRS and the average price target is 3.06 USD. This implies a price increase of 106.76% is expected in the next year compared to the current price of 1.48.
For the next year, analysts expect an EPS growth of 82.41% and a revenue growth 2.99% for UTRS